MedTrace Logo

Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana

NCT01459146 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 345

Last updated 2011-10-25

No results posted yet for this study

Summary

The purpose of this study is to determine if Artemisinin-based Combination Therapy, ACT,(artemether-lumefantrine) used as intermittent preventive treatment (IPT) alone or in combination with praziquantel, will have any effects on anemia, malaria, schistosomiasis and school sustained attention and concentration.

Conditions

  • Malaria
  • Schistosomiasis
  • Helminthiasis
  • Anemia
  • Change in Sustained Attention

Interventions

DRUG

Artemether-lumefantrine combination plus albendazole

AL: 20mg/120mg 12-hourly orally for 3 days ABZ: 400mg oral stat

DRUG

Artemether-lumefantrine plus Praziquantel plus Albendazole

Artemether-lumefantrine 20mg/120mg 12 hourly for 3 days, plus praziquantel 40mg/kg stat, plus albendazole 400mg stat oral

DRUG

Albendazole plus Praziquantel

Albendazole 400mg stat plus Praziquantel 40mg/kg stat oral

Sponsors & Collaborators

  • DBL -Institute for Health Research and Development

    collaborator OTHER

  • Navrongo Health Research Centre, Ghana

    lead OTHER

Principal Investigators

  • Ernest C Opoku, MD, MPH · Navrongo Health Research Centre, Ghana

  • Pascal Magnussen, MD · University of Copenhagen

  • Abraham V Hodgson, MD, MPH, PhD · Navrongo Health Research Centre, Ghana

  • Edmund L Browne, MD, MPH, PhD · University of Development Studies

  • Annette Olsen, PhD · University of Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2011-10-31
Completion
2012-11-30

Countries

  • Ghana

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01459146 on ClinicalTrials.gov